Women Underrepresented in Cardiovascular Trials

Recent research conducted by investigators at the Smidt Heart Institute at Cedars-Sinai has drawn attention to a significant discrepancy in the representation of women in clinical trials for cardiovascular conditions. Despite cardiovascular disease being a leading cause of mortality among women, participation among this demographic in relevant studies has been critically low. This article discusses the findings of the study, focusing on women's participation from 2017 to 2023 in cardiovascular trials.

The Importance of Representation in Clinical Trials

The underrepresentation of women in clinical trials can lead to gaps in understanding how certain medical conditions and treatments specifically affect them. As Martha Gulati, MD, director of Preventive Cardiology in the Smidt Heart Institute, stated, "Numbers don't lie." This encourages a call for researchers to ensure that clinical trials reflect actual populations affected by cardiovascular diseases.

Gulati's team presented their findings at the European Society of Cardiology Congress in Madrid, with results published simultaneously in JAMA Network Open. An overview of the participation levels is detailed in the table below:

Key Findings

The analysis of data from 1,079 cardiovascular clinical trials revealed that women represented only 41% of total participants. However, the participation rates varied significantly across different conditions:

• Coronary Heart Disease: Only 30% of participants were women.
• Acute Coronary Syndrome: Female participation stood at 35%.
• Stroke: Women accounted for 40% of participants.
• Obesity Studies: Higher female representation at 60%.

The investigators found that women aged 19 to 55 were more likely to participate in trials compared to those aged 61 and older. Additionally, female participants showed a tendency to enroll in studies that focused on lifestyle interventions rather than those involving procedural studies.

Recommendations and Future Directions

To bridge the gap in female representation in clinical trials, several recommendations were made:

• Continued Recruitment: Studies should ideally continue enrollment until the ratio of female participants reflects the proportions of women with the condition being studied.
• Enhanced Outreach: Improved efforts to reach out to female patients are necessary, ensuring that all women, particularly those with varying age demographics, are well-informed about clinical trial opportunities.

“Although we've made progress, critical gaps persist,” remarked Susan Cheng, MD, MPH, co-author of the study. “It's important to ensure that what we learn from research can be applied to women, who represent more than half of the world's population.”

Conclusion

The findings of this study underscore the necessity for equitable representation in clinical trials. Women's health issues, particularly in the realm of cardiovascular diseases, require targeted research that accurately reflects the entire population affected. As our understanding of women’s responses to cardiovascular conditions evolves, so should the research methods adopted to include them prominently.

Further Reading

For more detailed insights, refer to the published study: Participation of Women in Cardiovascular Trials From 2017 to 2023 by Frederick Berro Rivera et al in JAMA Network Open (2025).

References

[1] Gulati, M. et al. (2025). Participation of Women in Cardiovascular Trials From 2017 to 2023. JAMA Network Open.